ClinicalTrials.gg
CompletedNCT05089864STARUpdated Oct 24, 2025

STAR and Deferred Stenting Study

An interventional study of Stent Placement Timing - Early and Stent Placement Timing - Late in Coronary Occlusion, Coronary Stenosis and Coronary Restenosis, sponsored by Saint Luke's Health System. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-24.

Sponsored by Saint Luke's Health System · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Coronary Occlusion with a site in United States — 1 open to participants now, 1 under way, 1 of them phase 3. Coronary Occlusion · United States.

Enrollment
6th of 10
150 · median 153
Started
2021
the only one that year
No phase
4 of 13
none open now
Registered
11th of 13
by date

Among the 13 studies in Coronary Occlusion with a site in United States, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2021, is one of 4 with no phase, and was the 11th registered.

Coronary Occlusion

71 studies on the registry are indexed under Coronary Occlusion; 11 are open to participants now.

Browse Coronary Occlusion studies →

Open to participants now

1 of the 13 studies in Coronary Occlusion with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Coronary Occlusion studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Coronary Occlusion with a site in United States, or all of them as a file.
02

Study summary

STAR is a minimal-risk pragmatic clinical trial of patients admitted for a CTO-PCI procedure. The overall objective of the STAR Study is to address the current gaps in knowledge regarding use of STAR during CTO-PCI, as a prospective, multi-center study of 150 participants with randomization of timing of staged PCI. Five sites will be selected to participate in STAR from a national network of highly experienced CTO-PCI centers across the United States.

Read the detailed description

To date, there have been no studies that prospectively and systemically evaluated the efficacy and safety of STAR with deferred stenting and described the frequency of its use in the hybrid approach. The aim of this study is to address these current gaps in knowledge, including the frequency of use of STAR by experienced operators, the safety of its use, optimal timing of staged stenting and health status change associated with this procedure. This prospective study will enroll 150 patients undergoing elective PCI of native CTO utilizing the STAR technique and will subsequently randomize patients in a 1:1 fashion to early (5-7 weeks) and later (12-14 weeks) timing of subsequent stenting.

03

Conditions studied

  • Coronary Occlusion
  • Coronary Stenosis
  • Coronary Restenosis

Keywords

  • chronic total occlusion
  • sub-intimal plaque modification
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is scheduled for a PCI procedure for at least one chronic total occlusion with TIMI antegrade flow of zero.
  2. Subject is ≥ 18 years of age at the time of consent
  3. The operator attempted STAR technique defined as knuckle guidewire across or into the CTO segment during the CTO PCI and is planned for a staged procedure.
  4. English speaking due to follow up.

Exclusion criteria

Exclusion Criteria:

  1. The CTO segment is in a graft.
  2. Female subjects with a positive quantitative or qualitative pregnancy test, in accordance with hospital policy.
  3. Unable to participate in telephone follow-up

    1. Too hard of hearing to do follow-up by telephone or deaf.
    2. Incarcerated prisoner.
    3. History of dementia.
    4. Subjects without a way for contact by telephone for follow-up.
  4. Previously enrolled in STAR.
  5. Patient not a candidate for baseline and final angiography (CKD with \<30).
  6. The knuckled guidewire did not cross into the CTO segment during STAR attempt.
  7. A stent was placed into the STAR segment during the Index Procedure.
  8. Refused participation in the study.
  9. Patient enrolled in another study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Other
    Early stent placement

    Stent placement 5-7 weeks post-STAR procedure

    Other: Stent Placement Timing - Early

  • Other
    Later stent placement

    Stent placement 12-14 weeks post-STAR procedure

    Other: Stent Placement Timing - Late

Interventions

  • OtherStent Placement Timing - Early

    Stent placement 5-7 weeks after STAR procedure

  • OtherStent Placement Timing - Late

    Stent placement 12-14 weeks after STAR procedure

06

What researchers measure

Primary outcomes

  1. Staged Procedure Success

    success of the staged stenting procedure will be core lab adjudicated and defined as TIMI 3 flow, no major side branch loss, and residual stenosis \<30%

    Time frame: 14 weeks

Secondary outcomes

  1. Vessel patency at time of staged stenting procedure

    number of distal branches, and the antegrade TIMI flow through the vessel, assessed by core-lab analysis

    Time frame: 14 weeks

07

Study locations

1 site
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
08

References and documents

Publications

  • Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, Rumoroso JR, Erglis A, Christiansen EH, Escaned J, di Mario C, Hovasse T, Teruel L, Bufe A, Lauer B, Bogaerts K, Goicolea J, Spratt JC, Gershlick AH, Galassi AR, Louvard Y; EUROCTO trial investigators. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018 Jul 7;39(26):2484-2493. doi: 10.1093/eurheartj/ehy220. PubMed 29722796 ↗
  • Sapontis J, Salisbury AC, Yeh RW, Cohen DJ, Hirai T, Lombardi W, McCabe JM, Karmpaliotis D, Moses J, Nicholson WJ, Pershad A, Wyman RM, Spaedy A, Cook S, Doshi P, Federici R, Thompson CR, Marso SP, Nugent K, Gosch K, Spertus JA, Grantham JA. Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty: A Report From the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures). JACC Cardiovasc Interv. 2017 Aug 14;10(15):1523-1534. doi: 10.1016/j.jcin.2017.05.065. PubMed 28797429 ↗
  • Brilakis ES, Grantham JA, Rinfret S, Wyman RM, Burke MN, Karmpaliotis D, Lembo N, Pershad A, Kandzari DE, Buller CE, DeMartini T, Lombardi WL, Thompson CA. A percutaneous treatment algorithm for crossing coronary chronic total occlusions. JACC Cardiovasc Interv. 2012 Apr;5(4):367-79. doi: 10.1016/j.jcin.2012.02.006. PubMed 22516392 ↗
  • Hirai T, Grantham JA, Sapontis J, Cohen DJ, Marso SP, Lombardi W, Karmpaliotis D, Moses J, Nicholson WJ, Pershad A, Wyman RM, Spaedy A, Cook S, Doshi P, Federici R, Nugent K, Gosch KL, Spertus JA, Salisbury AC; OPEN CTO Study Group. Impact of subintimal plaque modification procedures on health status after unsuccessful chronic total occlusion angioplasty. Catheter Cardiovasc Interv. 2018 May 1;91(6):1035-1042. doi: 10.1002/ccd.27380. Epub 2017 Oct 25. PubMed 29068126 ↗
  • Hirai T, Grantham JA, Gosch KL, Patterson C, Kirtane AJ, Lombardi W, Nicholson WJ, Moses J, Karmpaliotis D, Salisbury AC. Impact of Subintimal or Plaque Modification on Repeat Chronic Total Occlusion Angioplasty Following an Unsuccessful Attempt. JACC Cardiovasc Interv. 2020 Apr 27;13(8):1010-1012. doi: 10.1016/j.jcin.2020.01.214. No abstract available. PubMed 32327084 ↗
  • Galassi AR, Boukhris M, Tomasello SD, Marza F, Azzarelli S, Giubilato S, Khamis H. Long-term clinical and angiographic outcomes of the mini-STAR technique as a bailout strategy for percutaneous coronary intervention of chronic total occlusion. Can J Cardiol. 2014 Nov;30(11):1400-6. doi: 10.1016/j.cjca.2014.07.016. Epub 2014 Jul 22. PubMed 25442438 ↗
  • Goleski PJ, Nakamura K, Liebeskind E, Salisbury AC, Grantham JA, McCabe JM, Lombardi WL. Revascularization of coronary chronic total occlusions with subintimal tracking and reentry followed by deferred stenting: Experience from a high-volume referral center. Catheter Cardiovasc Interv. 2019 Feb 1;93(2):191-198. doi: 10.1002/ccd.27783. Epub 2018 Nov 9. PubMed 30411863 ↗
  • Xenogiannis I, Choi JW, Alaswad K, Khatri JJ, Doing AH, Dattilo P, Jaffer FA, Uretsky B, Krestyaninov O, Khelimskii D, Patel M, Mahmud E, Potluri S, Koutouzis M, Tsiafoutis I, Jaber W, Samady H, Jefferson BK, Patel T, Megaly MS, Hall AB, Vemmou E, Nikolakopoulos I, Rangan BV, Abdullah S, Garcia S, Banerjee S, Burke MN, Brilakis ES. Outcomes of subintimal plaque modification in chronic total occlusion percutaneous coronary intervention. Catheter Cardiovasc Interv. 2020 Nov;96(5):1029-1035. doi: 10.1002/ccd.28614. Epub 2019 Dec 4. PubMed 31797507 ↗
  • Azzalini L, Kearney K, Salisbury AC, Stone N, Gosch KL, Jones PG, Spertus JA, Pershad A, Nicholson W, Lombardi W, Wyman RM, Davies R, Grantham JA, Hirai T; STAR Study Group. Early vs Late Staged PCI After Subintimal Tracking and Re-Entry for Chronic Total Occlusions: A Randomized Trial. J Am Coll Cardiol. 2026 Jan 27;87(3):286-293. doi: 10.1016/j.jacc.2025.09.1598. Epub 2025 Nov 26. PubMed 41295935 ↗
  • Hirai T, Kearney K, Azzalini L, Salisbury AC, Stone N, Gosch KL, Pershad A, Nicholson W, Lombardi W, Wyman RM, Davies R, Grantham JA; STAR Study Group. Optimal timing of staged percutaneous coronary intervention after subintimal tracking and re-entry: Rationale and design of the subintimal tracking and re-entry with deferred stenting study. Catheter Cardiovasc Interv. 2024 Sep;104(3):444-450. doi: 10.1002/ccd.31161. Epub 2024 Jul 24. PubMed 39044659 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Aug 2025, 44 months.

Of 16 interventional studies with no phase under Coronary Occlusion, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 44 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2021
First posted
Oct 22, 2021
StartActual
Nov 23, 2021
Primary completionActual
Aug 7, 2025
CompletionActual
Aug 7, 2025
Last update
Oct 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05089864
Lead sponsor
Saint Luke's Health System
Collaborators
Asahi-Intecc
Responsible party
Sponsor
First posted
Oct 22, 2021
Start date
Nov 23, 2021
Primary completion
Aug 7, 2025
Completion
Aug 7, 2025
Last update
Oct 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion